LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

LB Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street’s consensus is “Moderate Buy”: Ten of 13 analysts rate LB Pharmaceuticals a buy, two say hold and one says sell; the average one-year price target is $57.40. Needham and Canaccord initiated coverage with buy ratings and targets of $68 and $65, respectively.
  • The company reported a quarterly loss of $1.79 per share, missing analysts’ estimate of a $1.61 loss. Analysts expect a full-year loss of $6.05 per share on average.
  • LB Pharmaceuticals is a clinical-stage drug developer whose lead candidate, LB-102, is being studied for schizophrenia; it is investigational and has not been approved for commercial use.
  • MarketBeat previews top five stocks to own in December.

Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $57.40.

Several equities analysts have issued reports on the stock. Needham & Company LLC assumed coverage on shares of LB Pharmaceuticals in a research note on Friday, October 2nd. They issued a "buy" rating and a $68.00 price objective on the stock. Canaccord Genuity Group assumed coverage on shares of LB Pharmaceuticals in a research note on Friday, October 9th. They issued a "buy" rating and a $65.00 target price for the company. Wall Street Zen downgraded shares of LB Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Sunday, November 8th. BMO Capital Markets boosted their price target on shares of LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Finally, Zacks Research raised shares of LB Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, November 10th.

View Our Latest Stock Analysis on LB Pharmaceuticals

Hedge Funds Weigh In On LB Pharmaceuticals

Large investors have recently modified their holdings of the business. Spruce Street Capital LP boosted its position in shares of LB Pharmaceuticals by 36.9% during the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company's stock worth $33,645,000 after purchasing an additional 370,566 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of LB Pharmaceuticals in the first quarter valued at approximately $1,613,000. Bank of New York Mellon Corp acquired a new stake in LB Pharmaceuticals during the 2nd quarter valued at $1,784,000. Stempoint Capital LP purchased a new position in LB Pharmaceuticals during the first quarter worth $1,233,000. Finally, Sigma Planning Corp purchased a new position in LB Pharmaceuticals during the third quarter worth $1,151,000.

LB Pharmaceuticals Price Performance

LB Pharmaceuticals stock opened at $42.99 on Friday. LB Pharmaceuticals has a fifty-two week low of $15.13 and a fifty-two week high of $50.16. The stock has a 50-day simple moving average of $40.06 and a 200-day simple moving average of $33.59.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($1.79) EPS for the quarter, missing analysts' consensus estimates of ($1.61) by ($0.18). On average, research analysts anticipate that LB Pharmaceuticals will post -6.05 earnings per share for the current fiscal year.

About LB Pharmaceuticals

(Get Free Report)

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company's lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.

Recommended Stories

Analyst Recommendations for LB Pharmaceuticals (NASDAQ:LBRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LB Pharmaceuticals Right Now?

Before you consider LB Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LB Pharmaceuticals wasn't on the list.

While LB Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines